The use of α-particle emitters in radioimmunotherapy (RIT) appears to be promising. We
previously obtained convincing results in the treatment of microscopic intraperitoneal …

The α-emitter 211At labeled to a monoclonal antibody has proven safe and effective in
treating microscopic ovarian cancer in the abdominal cavity of mice. Women in complete …

The goal of this study was to investigate whether targeted α-therapy can be used to
successfully treat macrotumors, in addition to its established role for treating micrometastatic …

OBJECTIVE: The aim of this study was to investigate the therapeutic efficacy and
myelotoxicity during fractionated radioimmunotherapy of ovarian cancer in mice. The study …

Purpose: To elucidate the therapeutic efficacy of α-radioimmunotherapy of ovarian cancer in
mice. This study:(i) estimated the minimum required activity (MRA), giving a reasonable high …

The purpose of this study was to investigate the therapeutic efficacy of—and to estimate the
absorbed dose to—tumor cells from radioimmunotherapy (RIT) in an ovarian cancer model …

Eliminating microscopic residual disease with α-particle radiation is theoretically appealing.
After extensive preclinical work with α-particle–emitting 211At, we performed a phase I trial …

Purpose: The aim of this study was to investigate the therapeutic efficacy of the alpha-
radioimmunotherapy of ovarian cancer in mice, using different specific activities. This study …

Purpose The radionuclide 186Re has favorable physical characteristics for use in
radioimmunotherapy, including the emission of beta-particles of a high-energy and a low …

The aim of this study was to investigate the therapeutic efficacy of α-radioimmunotherapy of
ovarian cancer in mice using different fractionated treatment regimens. The study was …